Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells

Vieira, Alexandre C.C.; Chaves, Luíse L.; Pinheiro, Marina; Ferreira, Domingos; Sarmento, Bruno; Reis, Salette

doi:10.2147/ijn.s104908

Cited by 25 publications

(15 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of monocyte-macrophage cell based nanoparticle drug carriage can improve the pharmacokinetic and pharmacodynamic profiles for treatment of human immunodeficiency virus (HIV), inflammatory and degenerative disorders [1–18]. A major obstacle for bench to bedside translation of the cell based nanoparticles rests in optimizing drug particle tissue biodistribution.…”

Section: Introductionmentioning

confidence: 99%

Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging

et al. 2017

View full text Add to dashboard Cite

The size, shape and chemical composition of europium (Eu3+) cobalt ferrite (CFEu) nanoparticles were optimized for use as a “multimodal imaging nanoprobe” for combined fluorescence and magnetic resonance bioimaging. Doping Eu3+ ions into a CF structure imparts unique bioimaging and magnetic properties to the nanostructure that can be used for real-time screening of targeted nanoformulations for tissue biodistribution assessment. The CFEu nanoparticles (size ~7.2 nm) were prepared by solvothermal techniques and encapsulated into poloxamer 407-coated mesoporous silica (Si-P407) to form superparamagnetic monodisperse Si-CFEu nanoparticles with a size of ~ 140 nm. Folic acid (FA) nanoparticle decoration (FA-Si-CFEu, size ~ 140 nm) facilitated monocyte-derived macrophage (MDM) targeting. FA-Si-CFEu MDM uptake and retention was higher than seen with Si-CFEu nanoparticles. The transverse relaxivity of both Si-CFEu and FA-Si-CFEu particles were r2= 433.42 mM−1s−1 and r2= 419.52 mM−1s−1 (in saline) and r2= 736.57 mM−1s−1 and r2= 814.41 mM−1s−1 (in MDM), respectively. The results were greater than a log order-of-magnitude than what was observed at replicate iron concentrations for ultrasmall superparamagnetic iron oxide (USPIO) particles (r2= 31.15 mM−1s−1 in saline) and paralleled data sets obtained for T2 magnetic resonance imaging. We now provide a developmental opportunity to employ these novel particles for theranostic drug distribution and efficacy evaluations.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The 3-level, 3-factor design evaluates three independent factors with a fewer number of experiments based on a collection of mathematical and statistical techniques, which leads to reagent savings and to less time-consuming laboratory work [24,25]. In the last decades, the Box-Behnken design has been applied to optimize the process of several drug-loaded nanoparticle formulations [13][14][15][16][17][18].…”

Section: Resultsmentioning

confidence: 99%

“…The decreases in the ΔH, melting point, and in the onset temperature were in full agreement with the high entrapment efficacy of RPT in the NLCs. In fact, the presence of the drug is expected to increase the number of defects in the lipid matrix of lipid nanoparticles, creating a disturbance in the crystal order that leads to a decrease of the lipid melting point [17,26]. To evaluate the morphology of the optimized NLCs, TEM was performed.…”

Section: Samplesmentioning

confidence: 99%

“…Nanoparticles, namely lipid nanoparticles, are considered biodegradable, safe, and constitute a promising strategy for easier and shorter treatment regimens. In the last recent years, quality-by-design studies using response surface methodologies have been used to optimize several drug-loaded nanoformulations [13][14][15][16][17][18]. Accordingly, the present work proposes the optimization and development of nanostructured lipid carriers (NLCs) loaded with RPT as a new delivery system for TB treatment.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy

et al. 2020

Self Cite

View full text Add to dashboard Cite

This work aims to optimize and assess the potential use of lipid nanoparticles, namely nanostructured lipid carriers (NLCs), as drug delivery systems of rifapentine (RPT) for the treatment of tuberculosis (TB). A Box–Behnken design was used to increase drug encapsulation efficiency (EE) and loading capacity (LC) of RPT-loaded NLCs. The optimized nanoparticles were fully characterized, and their effect on cell viability was assessed. The quality-by-design approach allowed the optimization of RPT-loaded NLCs with improved EE and LC using the minimum of experiments. Analyses of variance were indicative of the validity of this model to optimize this nanodelivery system. The optimized NLCs had a mean diameter of 242 ± 9 nm, polydispersity index <0.2, and a highly negative zeta potential. EE values were higher than 80%, and differential scanning calorimetry analysis enabled the confirmation of the efficient encapsulation of RPT. Transmission electron microscopy analysis showed spherical nanoparticles, uniform in shape and diameter, with no visible aggregation. Stability studies indicated that NLCs were stable over time. No toxicity was observed in primary human macrophage viability for nanoparticles up to 1000 μg mL−1. Overall, the optimized NLCs are efficient carriers of RPT and should be considered for further testing as promising drug delivery systems to be used in TB treatment.

show abstract

“…65 The targeting of activated macrophages via recognition of their overexpressed surface receptors has also been applied in NP-based cell-specific therapies for IBD. The relevant studies used mannosylated poly-(amidoamine)-based NPs to target mannose, 66 galactosylated chitosan NPs to target the macrophage galactose/N-acetyl galactosamine-specific lectins (MGLs), [67][68][69] and PLA-PEG NPs grafted with the Fab' portion of F4/80 antibodies to target the F4/80 membrane proteins. 70 These studies showcased the power of NPs to target specific cells through ligand/receptor interactions.…”

Section: Immune Cells the Lamina Propria And The Extracellular Matrixmentioning

confidence: 99%

<p>Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives</p>

Yang¹,

Merlin²

2019

IJN

125

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), which mainly consists of Crohn's disease and ulcerative colitis, is a chronic and relapsing inflammatory condition of the gastrointestinal tract. The traditional treatment strategies relied on frequent administration of high dosages of medications, including antibiotics, non-steroidal anti-inflammatory drugs, biologics, and immunomodulators, with the goal of reducing inflammation. Some of these medications were effective in alleviating the early-stage inflammatory symptoms, but their long-term efficacies were compromised by the accumulation of toxicities. Recently, nanoparticle (NP)based drugs have been widely studied for their potential to solve such problems. Various mechanisms/strategies, including size-, charge-, pH-, pressure-, degradation-, ligand-receptor-, and microbiome-dependent drug delivery systems, have been exploited in preclinical studies. A certain number of NP delivery systems have sought to target drugs to the inflamed intestine. Although several NP-based drugs have entered clinical trials for the treatment of IBD, most have failed due to premature drug release, weak targeting ability, and the high immune toxicity of some of the synthetic nanomaterials that have been used to fabricate the NPs. Therefore, there is still a need for rationally designed and stable NP drug delivery system that can specifically target drugs to the disease site, prolong the drug's residence time, and minimize systemic side effects. This review will analyze the current state of the art in NP-mediated drug delivery for IBD treatment. We will focus on topics such as deliverable targets (at the tissue or cellular level) for treating inflammation; the target-homing NP materials that can interact with such targets; and the major administration routes for treating IBD. These discussions will integrate notable trends in the research and development of IBD medications, including multi-responsive NP-mediated delivery and naturally-derived targeting NPs. Finally, current challenges and future directions will be presented in the hopes of advancing the study of NP-mediated strategies for treating IBD.

show abstract

Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells

Cited by 25 publications

References 64 publications

Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging

Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging

Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy

<p>Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives</p>

Contact Info

Product

Resources

About